You walk into a room and your first thought is where the nearest toilet is. You plan car journeys, meetings and the weekly shop around the breaks. At night you wake two or three times because your bladder is calling. Laughing, sneezing, cold water, the key in the lock of your front door: any of these can set off the urge. If you recognise yourself in this, urology calls it an overactive bladder (OAB). The condition is common, it is treatable, and you do not have to put up with it.

In short
Overactive bladder (OAB) is clinically defined as sudden, hard-to-suppress urinary urgency, usually with frequent urination during the day and at night, with or without urge incontinence, provided that infection or other obvious pathology has been excluded [Haylen BT et al., Neurourol Urodyn 2010]. The prevalence of OAB in the adult general population in Europe is around 12 per cent, rising markedly in older age groups [Irwin DE et al., Eur Urol 2006]. The European Association of Urology recommends a stepped approach to treatment: behavioural therapy and pelvic floor training first, then medication (antimuscarinics or beta-3 agonists), and where treatment fails, invasive options such as botulinum toxin injection into the detrusor or sacral neuromodulation [EAU Guidelines on Non-Neurogenic Female LUTS, 2024]. The first step is always to rule out a urinary tract infection, haematuria and relevant comorbidities. From there follows an individual treatment plan, which is extended only when the gentler stage proves insufficient.

What an overactive bladder really is

The detrusor, the bladder muscle, is normally relaxed while the bladder fills. Only once a certain volume is reached does a nerve feedback loop signal the urge, and you decide when to go to the toilet. In an overactive bladder this control is disturbed. The muscle contracts even at low filling volumes, the urge comes on suddenly, is hard to control and returns often.

The International Continence Society defines OAB by four cardinal symptoms: urgency as the core symptom, frequency (daytime voiding more than seven times), nocturia (waking at night to urinate) and, optionally, urge incontinence (involuntary urine loss immediately after the urgency) [Haylen BT et al., Neurourol Urodyn 2010]. One symptom alone is not enough for the diagnosis. It is the cluster that makes the condition.

The causes are rarely a single trigger. Changes in the detrusor muscle itself, the afferent nerves, the urothelial sensory system and control circuits in the brainstem all play a part. Hormonal changes after the menopause, previous childbirth, a weakened pelvic floor, chronic constipation, some underlying neurological conditions (multiple sclerosis, Parkinson's disease) and certain groups of medication can trigger or aggravate the picture. OAB has nothing to do with age or personal weakness. It is a treatable neuromuscular dysfunction.

OAB is not the same as stress incontinence

The most common mix-up in the consulting room is between urge incontinence and stress incontinence. Clinically and therapeutically, these are two different conditions.

With stress incontinence you lose urine at the moment the pressure inside your abdomen rises: when coughing, sneezing, laughing, lifting, climbing stairs. There is no urge. The cause is usually a weak sphincter or a weakened pelvic floor structure, often after pregnancy and childbirth or after the menopause.

With urge incontinence you lose urine after a sudden, barely suppressible urge. Often you no longer reach the toilet in time, and sometimes you lose urine as the key goes into the lock (the so-called key-in-the-lock effect). The cause is an overactive bladder.

Mixed incontinence combines both mechanisms. In population-based data, pure urge incontinence accounts for roughly a third of incontinent women, pure stress incontinence for roughly half, and the remainder is mixed incontinence [Irwin DE et al., Eur Urol 2006]. Telling them apart matters because the treatment differs: pelvic floor training and, where appropriate, surgical options for stress incontinence; behavioural therapy and medication to calm the detrusor for OAB. Whoever fails to separate the two treats the wrong problem.

How we investigate

The diagnostic work-up for an overactive bladder is thorough but not elaborate. Equipment is the exception; the conversation is the rule.

  1. History and symptom score. We take your story: When did it start? Which triggers have you noticed? How often during the day, how often at night? How much does it affect your daily life? Standardised questionnaires (for example the ICIQ-OAB) help to put the symptoms into objective terms and to measure progress during treatment.

  2. Voiding diary (bladder diary). For three days you keep a record: fluid intake, toilet visits with the time and estimated volume, episodes of urgency, pad changes. In 72 hours this diary delivers more objective information than any instrumental test at a first visit.

  3. Urinalysis and urine culture. Before we speak of an overactive bladder, we rule out a urinary tract infection. This step is mandatory. Recurrent cystitis can imitate OAB symptoms perfectly.

  4. Bladder ultrasound. By ultrasound we measure the residual volume of urine after voiding. A raised residual volume changes the treatment fundamentally, because antimuscarinics are unsuitable in this situation.

  5. Targeted additional tests when something is abnormal. In cases of haematuria, treatment-resistant courses, a neurological history or a suspected pelvic floor pathology, we refer you to urology, urogynaecology or neurology as appropriate. Urodynamic testing belongs in specialist hands and is not routine in the initial work-up [EAU Guidelines on Non-Neurogenic Female LUTS, 2024].

The aim of this work-up is the right treatment stage, not the maximum number of findings.

Treatment comes in stages

The EAU recommends a clearly stepped structure. We start with the gentlest effective stage and extend it only where necessary.

Stage 1: behavioural therapy and pelvic floor. Adjusting fluid intake (typically between 1.5 and 2 litres a day, depending on climate and activity), cutting back on irritants such as caffeine and alcohol in the evening, bladder training with gradual lengthening of the intervals between toilet visits, and targeted pelvic floor training under physiotherapy guidance. This stage is no warm-up act. It is the first-choice measure recommended in the EAU guidelines for OAB and urge incontinence, and applied consistently for at least twelve weeks it brings relevant symptom reduction in many patients [EAU Guidelines on Non-Neurogenic Female LUTS, 2024; Nambiar AK et al., Eur Urol 2022].

Stage 2: medication. Two classes of drug are available. Antimuscarinics (solifenacin, tolterodine, trospium chloride, darifenacin, fesoterodine) block the muscarinic receptors on the detrusor and reduce the uncontrolled contractions. Beta-3 agonists (mirabegron, vibegron) relax the detrusor by a different mechanism and generally have a more favourable side-effect profile with regard to dry mouth, constipation and cognition. The choice depends on age, comorbidities, other medication and individual response. In older patients with cognitive concerns we often prefer beta-3 agonists to antimuscarinics.

Stage 3: invasive options where treatment fails. If the first two stages do not work sufficiently after at least three months of consistent use, invasive procedures come into play. Botulinum toxin injection into the detrusor muscle, performed by a urologist via cystoscopy, works for a median of six to nine months and can be repeated. Sacral neuromodulation uses an implanted pacemaker to modulate the nerve control of the bladder. Percutaneous tibial nerve stimulation is a gentler, non-invasive alternative offered in specialised centres. The indication for these procedures is decided jointly with urology [Nambiar AK et al., Eur Urol 2022].

In our GP practice we cover stages 1 and 2 in full. For stage 3 we work closely with our urology colleagues in Zürich and take over the follow-up care after the procedure.

When you belong in urology

Most women with an overactive bladder are correctly investigated and successfully treated by their GP. There are, however, clear signals that make us refer you directly to urology:

  • Visible or microscopic blood in the urine (haematuria) without a urinary tract infection to explain it.
  • Raised residual urine above 100 ml on ultrasound.
  • Treatment failure after three months of guideline-based treatment at stages 1 and 2.
  • Accompanying neurological symptoms (sensory loss, leg weakness, new back pain together with bladder problems): these call for prompt neurological assessment first, ahead of urology.
  • Suspected pelvic organ prolapse (a feeling of pressure, a bulge, pain): to urogynaecology.

A referral like this is simply division of labour. Whoever takes the right step at the right time is free of symptoms sooner.

  • Keep a three-day voiding diary before you come to the consultation. It saves an appointment and makes the diagnosis more precise.
  • Cut back on caffeine and alcohol, especially after 5 pm. Both irritate the detrusor and drive urine production.
  • Drink regularly across the day rather than in two large amounts. 1.5 to 2 litres is the usual target.
  • Start pelvic floor training under the guidance of a physiotherapist who specialises in urogynaecology. Online programmes are no substitute.
  • Write down your triggers: cold water, stress, certain foods. Knowing the patterns gives you back control.
  • Talk openly with your GP. Embarrassment, far more than age, is the most common reason a diagnosis comes late.

Consultation at Dein Team fürs Leben

First contact without a referral. Appointments usually within a week. A confidential conversation, careful diagnostics, a clear treatment plan.

Book an appointment

Frequently asked questions

Is an overactive bladder a sign of ageing?
It becomes more common with age, but it is no inevitable part of getting older. In the EPIC study the overall prevalence of OAB was around 12 per cent, rising markedly in older age groups \[Irwin DE et al., Eur Urol 2006\]. It is treatable at any age.

How long does it take for the treatment to work?

Behavioural therapy and pelvic floor training typically show their first effects after four to six weeks, with the full effect setting in after about twelve weeks. Medication works sooner, usually within two to four weeks, but should be taken consistently for at least eight weeks before treatment failure is assumed.

Do antimuscarinics really cause dementia?

A concern that is rightly debated. Observational studies show an association between long-term anticholinergic burden and an increased risk of dementia, particularly in older patients. The data do not, however, prove a causal relationship. In practice, for patients over 65 or with pre-existing cognitive conditions, we often prefer the beta-3 agonists (mirabegron, vibegron) to antimuscarinics [EAU Guidelines on Non-Neurogenic Female LUTS, 2024].

Does hormone replacement therapy help with OAB after the menopause?

Locally applied oestrogens (vaginal cream, vaginal tablets) can regenerate the urogenital mucosa in postmenopausal women and reduce urgency and irritative symptoms. Systemic hormone replacement therapy shows no clear benefit for OAB symptoms and is primarily reserved for other indications. Local therapy is safe and can be combined with the other stages.

What does the work-up cost at your practice?

Where there is a medical indication, the work-up is covered by compulsory health insurance (Grundversicherung). We bill under TARDOC, the Swiss outpatient tariff. A first consultation with history, urinalysis and bladder ultrasound takes 30 to 45 minutes. Reception helps with billing questions and issues international invoices directly.

Reviewed by Prof. Dr. Steffen Gloekler, FMH Cardiology, on 1 June 2026.